$PBIO South Easton, Massachusetts--(Newsfile Corp.
Post# of 250602
(Total Views: 131)
Posted On: 01/13/2020 1:01:15 PM
$PBIO South Easton, Massachusetts--(Newsfile Corp. - January 9, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that in 2019 - for the second straight year - over 20 scientific papers highlighting the advantages of PBI's patented pressure cycling technology ("PCT" platform were published worldwide. Authored by independent scientists from academia, government, and industry, these publications highlighted the powerful and enabling benefits of the PCT Platform in such critical areas as cancer research, food safety, and proteomics.
As in previous years, several papers were authored by scientists who are considered Key Opinion Leaders ("KOLs" in their respective scientific field. High quality papers authored by KOLs that are published in well-known, respected journals are an integral part of PBI's marketing strategy.
Ms. Roxana McCloskey, PBI's Global Director of Sales & Marketing, commented: "PCT-related scientific papers published in 2019 highlighted new and/or improved applications of the PCT Platform in a number of important and exciting areas of research, including cancer, food safety, and proteomics. We are particularly pleased that several publications described protocols for combining the PCT Platform with existing technologies from other companies to fill a significant unmet need for high throughput protein processing of cancer biopsy tissues."
Ms. McCloskey continued: "These new protocols highlight the advantages and power of PCT, the flexibility of the PCT Platform to meet the unique requirements of different research laboratories, and the ability of the PCT Platform to integrate well with other manufacturers' laboratory equipment. We are currently in discussions with several manufacturers of such equipment, believe that these discussions will lead to collaborative marketing, selling, and/or co-development programs with these manufacturers in early 2020, and that such collaborative programs will result in increased sales of the PCT Platform in 2020 and beyond."
https://www.barrons.com/articles/PR-CO-202001...mp;tesla=y
, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that in 2019 - for the second straight year - over 20 scientific papers highlighting the advantages of PBI's patented pressure cycling technology ("PCT" platform were published worldwide. Authored by independent scientists from academia, government, and industry, these publications highlighted the powerful and enabling benefits of the PCT Platform in such critical areas as cancer research, food safety, and proteomics. As in previous years, several papers were authored by scientists who are considered Key Opinion Leaders ("KOLs"
in their respective scientific field. High quality papers authored by KOLs that are published in well-known, respected journals are an integral part of PBI's marketing strategy. Ms. Roxana McCloskey, PBI's Global Director of Sales & Marketing, commented: "PCT-related scientific papers published in 2019 highlighted new and/or improved applications of the PCT Platform in a number of important and exciting areas of research, including cancer, food safety, and proteomics. We are particularly pleased that several publications described protocols for combining the PCT Platform with existing technologies from other companies to fill a significant unmet need for high throughput protein processing of cancer biopsy tissues."
Ms. McCloskey continued: "These new protocols highlight the advantages and power of PCT, the flexibility of the PCT Platform to meet the unique requirements of different research laboratories, and the ability of the PCT Platform to integrate well with other manufacturers' laboratory equipment. We are currently in discussions with several manufacturers of such equipment, believe that these discussions will lead to collaborative marketing, selling, and/or co-development programs with these manufacturers in early 2020, and that such collaborative programs will result in increased sales of the PCT Platform in 2020 and beyond."
https://www.barrons.com/articles/PR-CO-202001...mp;tesla=y
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼